NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Citius Pharmaceuticals, Inc. CTXR
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-3.38
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-57.8%
Net margin · FY25
—
Dividend coverage
-3.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -3.38
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-57.8%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-32.1%
Each USD of equity lost 58 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+12.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.0%
+12.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 130.9M
total assets, end of FY2025
Total assetsUSD 130.9M
EquityUSD 67.6M
CashUSD 4.3M
Current ratio0.62×
Equity funds 52% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.38
−5.97
−5.57
−0.23
−0.23
−0.45
−0.77
−1.17
−1.89
−2.29
−1.37
−0.04
−0.07
0.00
0.00
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
0.60
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−57.8
−49.0
−33.6
−28.6
−27.8
−57.7
−53.9
−47.7
−53.6
−102.9
·
·
·
·
·
−620.0
Shares out B
0.02
0.01
0.01
0.15
0.15
0.06
0.03
0.02
0.01
0.00
0.03
0.03
0.02
0.02
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed